Català, AlbaGalván-Casas, CristinaCarretero-Hernández, GregorioRodríguez-Jiménez, PedroFernández-Nieto, DanielRodríguez-Villa, AnaNavarro-Fernández, ÍñigoRuiz-Villaverde, RicardoFalkenhain-López, DanielLlamas-Velasco, MarCarnero-Gonzalez, LucíaGarcía-Gavin, JuanBaniandrés, OfeliaGonzález-Cruz, CarlosMorillas-Lahuerta, VíctorCubiró, XavierFigueras, IgnasiSelda-Enriquez, GeraldFustà-Novell, XavierRoncero-Riesco, MónicaBurgos-Blasco, PatríciaRomaní, JorgeSolà-Ortigosa, JoaquimGarcía-Doval, Ignacio2023-02-092023-02-092020-09-09http://hdl.handle.net/10668/16085A previous study has defined the maculopapular subtype of manifestations of COVID-19. The objective of our study was to describe and classify maculopapular eruptions associated with COVI-19. We carried out a subanalysis of the maculopapular cases found in the previous cross-sectional study. Using a consensus, we defined seven clinical patterns. We described patient demographics, the therapy received by the patient and the characteristics of each pattern. Consensus lead to the description of seven major maculopapular patterns: morbilliform (45.5%), other maculopapular (20.0%), purpuric (14.2%), erythema multiforme-like (9.7%), pytiriasis rosea-like (5.7%), erythema elevatum diutinum-like (2.3%), and perifollicular (2.3%). In most cases, maculopapular eruptions were coincident (61.9%) or subsequent (34.1%) to the onset of other COVID-19 manifestations. The most frequent were cough (76%), dyspnea (72%), fever (88%), and astenia (62%). Hospital admission due to pneumonia was frequent (61%). Drug intake was frequent (78%). Laboratory alterations associated with maculo-papular eruptions were high C-reactive protein, high D-Dimer, lymphopenia, high ferritin, high LDH, and high IL-6. The main limitation of our study was the impossibility to define the cause-effect relationship of each pattern. In conclusion, we provide a description of the cutaneous maculopapular manifestations associated with COVID-19. The cutaneous manifestations of COVID-19 are wide-ranging and can mimic other dermatoses.enCOVID-19coronaviruscutaneous manifestationsskinAdolescentAdultAgedAged, 80 and overAntiviral AgentsCOVID-19Cross-Sectional StudiesFemaleHost-Pathogen InteractionsHumansMaleMiddle AgedRisk FactorsSARS-CoV-2SkinSkin Diseases, ViralSpainYoung AdultCOVID-19 Drug Treatmentresearch article32779280open access10.1111/dth.141701529-8019PMC7436694https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436694https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436694/pdf